The expensive nature of doctor-recommended tests have led to high sales of self-diagnostic testing kits. Self-diagnostic kits are easily available in pharmacies and online. Self-monitoring blood glucose (SMBG) devices can be used by pediatrics and geriatrics to check their blood glucose levels. They can display predictive warnings regarding hypoglycemia and hyperglycemia.
Browse full research report at : https://goo.gl/gTJZGP
According to the World Health Organization (WHO), incidence of diabetes had risen to 422 million in 2014. If left untreated, it can lead to stroke, kidney failure, and heart attacks. Various governments have made it mandatory to include diabetic testing in health reimbursement schemes. These schemes are expected to lead to higher purchase of SMBGs and invoke a new revolution in diabetes management.
Integration to Mobile Applications
Three major types of SMBG devices are blood glucose lancets, blood glucose test strips, and blood glucose meters. Blood glucose meters can gauge high glucose levels instantly. They are integral to the geriatric populace or consumers unable to make hospital visits. Companies have devised a non-invasive method to detect glucose levels without causing patients any pain or discomfort. Glucobeam, a non-invasive device developed by RSP Systems, can detect glucose levels immediately. It can conduct nearly 4-8 tests in a day. In addition, the integration of SMBG meters with smartphone applications lets users check hyperglycemia levels against past tests.
Roche Diagnostics AG, a division of F. Hoffmann-La Roche AG, introduced two blood glucose meters, namely the Accu-Chek Guide and Accu-Chek Instant. Both these devices will be able to connect to Medtronic insulin pumps as a result of an agreement between Roche and Medtronic. This development will benefit consumers of both brands by providing blood sugar level data on a common platform. Both devices can share their readings with the help of a mobile application.
Market Overview
The global self-monitoring blood glucose devices market is projected to attain high revenue by 2022, according to a report on Radiant Insights, Inc. High prevalence of diabetes is expected to drive market growth over the forecast period (2017-2022). Current trend of self management of lifestyle diseases is projected to influence market demand during the forecast period. Increase in government healthcare expenditure can drive market sales. On the other hand, lack of consumer awareness regarding these devices and unclear government production guidelines may impede market growth.
Prominent market players include F. Hoffmann-La Roche AG, Bionime Corporation, Abbott Laboratories, and Medtronic Public Limited.
To get free request sample at :
No comments:
Post a Comment